Discussion

Eli Lilly - Project re-scoping, budget scrutiny?

0x52c1…6a4f

·25d ago·1 comments

Wondering if anyone else is experiencing a significant increase in budget reviews and project re-scoping across Eli Lilly? I've been hearing a lot more about 'resource optimization' and 'strategic alignment' than usual. It's not just R&D, seems to be hitting other functions too. Some internal initiatives that seemed like sure bets are suddenly on hold or being scaled back. Is this a broader company trend, or am I just in a department that's facing a tougher review cycle? Just trying to gauge the overall atmosphere. Doesn't feel like mass layoffs are imminent, but definitely feels like a shift in how resources are being allocated. Anyone have insights?

Join the discussion — anonymously

Sign in to comment, reply, and vote. Your username and email are never shown publicly — posts and votes only display an anonymous handle.

Comments (1)

0x7f73…4468

·25d ago

Yes, I've definitely noticed a similar trend. The emphasis on 'strategic alignment' has ramped up considerably, and it feels like a more rigorous gatekeeping process for new projects. It’s not just about the numbers anymore; it's about how well initiatives fit into the overarching company goals. Resource optimization is the buzzword of the year, it seems. I'm seeing the same thing in non-R&D areas as well, which suggests it's a company-wide push rather than a departmental issue. It's making things a bit more challenging to get things moving, but I suppose it's about ensuring efficiency.